Galectin Therapeutics, Inc. (GALT)
3.71
+0.07
(+1.92%)
USD |
NASDAQ |
Oct 15, 16:00
3.73
+0.02
(+0.54%)
After-Hours: 20:00
Galectin Therapeutics Cash from Operations (TTM) : -15.89M for June 30, 2026
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | -15.89M |
| March 31, 2026 | -20.05M |
| December 31, 2025 | -23.88M |
| September 30, 2025 | -30.62M |
| June 30, 2025 | -35.62M |
| March 31, 2025 | -37.35M |
| December 31, 2024 | -41.77M |
| September 30, 2024 | -33.68M |
| June 30, 2024 | -32.78M |
| March 31, 2024 | -34.28M |
| December 31, 2023 | -32.96M |
| September 30, 2023 | -35.50M |
| June 30, 2023 | -36.21M |
| March 31, 2023 | -33.81M |
| December 31, 2022 | -31.06M |
| September 30, 2022 | -30.77M |
| June 30, 2022 | -27.42M |
| March 31, 2022 | -25.97M |
| December 31, 2021 | -24.31M |
| September 30, 2021 | -22.77M |
| June 30, 2021 | -25.98M |
| March 31, 2021 | -22.61M |
| December 31, 2020 | -20.60M |
| September 30, 2020 | -18.95M |
| June 30, 2020 | -12.21M |
| Date | Value |
|---|---|
| March 31, 2020 | -11.94M |
| December 31, 2019 | -10.85M |
| September 30, 2019 | -9.096M |
| June 30, 2019 | -9.198M |
| March 31, 2019 | -9.947M |
| December 31, 2018 | -10.18M |
| September 30, 2018 | -12.08M |
| June 30, 2018 | -13.62M |
| March 31, 2018 | -15.54M |
| December 31, 2017 | -15.89M |
| September 30, 2017 | -16.85M |
| June 30, 2017 | -17.17M |
| March 31, 2017 | -16.78M |
| December 31, 2016 | -16.41M |
| September 30, 2016 | -16.14M |
| June 30, 2016 | -17.78M |
| March 31, 2016 | -16.16M |
| December 31, 2015 | -16.98M |
| September 30, 2015 | -15.50M |
| June 30, 2015 | -13.69M |
| March 31, 2015 | -13.12M |
| December 31, 2014 | -12.43M |
| September 30, 2014 | -10.96M |
| June 30, 2014 | -9.16M |
| March 31, 2014 | -8.68M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (TTM) Benchmarks
| Mirum Pharmaceuticals, Inc. | -227.27M |
| ACADIA Pharmaceuticals, Inc. | 160.32M |
| Alnylam Pharmaceuticals, Inc. | 885.89M |
| Anika Therapeutics, Inc. | 5.977M |
| Savara, Inc. | -110.38M |